Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed ...

Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. The French pharma in April joined forces with the UK ...

Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

Sanofi shares rose as much as 1.1% in Paris trading. GSK was little changed in London. Concerns about Sanofi’s and other drugmakers’ exposure to Zantac suits helped wipe out about $45 billion ...

A possible new coronavirus vaccine candidate produced by Sanofi and GSK (GlaxoSmithKline) that uses the human body’s own antigens to neutralize antibody responses for people who have already ...

Sanofi honing its focus on innovative medicines and vaccines while shedding its consumer health business is not unique. Johnson & Johnson (J&J) and GSK both made the same play in 2022, creating ...